Abstract：
UNASSIGNED: This systematic review study investigated the cost-effectiveness of stereotactic radiotherapy (SRT) and stereotactic radiosurgery (SRS) for treatment of various types of cancers.
UNASSIGNED: PubMed, Scopus, and Web of Science were searched from 30 December 1990 to 1 January 2023. The entered studies were screened in accordance with the inclusion criteria. The inclusion criteria encompassed all types of economic evaluation studies that investigated SRT/SRS technologies in the treatment of various cancers.
UNASSIGNED: A total of 47 articles were included in the review. The findings suggest that the use of Linear accelerator technology for the treatment of lung cancer (8 out of 12 studies) and prostate cancer (4 out of 5 studies) was a cost-effective strategy. Linear accelerator was found to be cost-effective in the treatment of liver metastases and liver cancer (2 out of 5 studies). All of the included studies that used Gamma Knife technology in brain metastases reported Gamma-Knife was a cost-effective treatment. Furthermore, in the treatment of prostate and liver cancer, proton therapy was identified as a cost-effective option than other treatments.
UNASSIGNED: This study confirms that SRT/SRS is a cost-effective procedure for the treatment of various types of cancers. Therefore, it is recommended to use SRT/SRS technology for optimal use of resources.
UNASSIGNED: PubMed, Scopus, and Web of Science were searched from 30 December 1990 to 1 January 2023. The entered studies were screened in accordance with the inclusion criteria. The inclusion criteria encompassed all types of economic evaluation studies that investigated SRT/SRS technologies in the treatment of various cancers.
UNASSIGNED: A total of 47 articles were included in the review. The findings suggest that the use of Linear accelerator technology for the treatment of lung cancer (8 out of 12 studies) and prostate cancer (4 out of 5 studies) was a cost-effective strategy. Linear accelerator was found to be cost-effective in the treatment of liver metastases and liver cancer (2 out of 5 studies). All of the included studies that used Gamma Knife technology in brain metastases reported Gamma-Knife was a cost-effective treatment. Furthermore, in the treatment of prostate and liver cancer, proton therapy was identified as a cost-effective option than other treatments.
UNASSIGNED: This study confirms that SRT/SRS is a cost-effective procedure for the treatment of various types of cancers. Therefore, it is recommended to use SRT/SRS technology for optimal use of resources.
摘要：
■这项系统综述研究调查了立体定向放射治疗（SRT）和立体定向放射外科（SRS）治疗各种类型癌症的成本效益。
■PubMed,Scopus,和WebofScience的搜索时间为1990年12月30日至2023年1月1日。根据纳入标准筛选进入的研究。纳入标准包括研究SRT/SRS技术治疗各种癌症的所有类型的经济评估研究。
■共包括47篇文章。研究结果表明，使用直线加速器技术治疗肺癌（12项研究中的8项）和前列腺癌（5项研究中的4项）是一种具有成本效益的策略。发现线性加速器在治疗肝转移和肝癌方面具有成本效益（5项研究中有2项）。所有在脑转移中使用伽玛刀技术的纳入研究都报道了伽玛刀是一种具有成本效益的治疗方法。此外，在前列腺癌和肝癌的治疗中，与其他治疗相比,质子治疗被认为是一种具有成本效益的选择.
■这项研究证实，SRT/SRS是用于治疗各种类型癌症的具有成本效益的程序。因此,建议使用SRT/SRS技术以优化资源使用。
■PubMed,Scopus,和WebofScience的搜索时间为1990年12月30日至2023年1月1日。根据纳入标准筛选进入的研究。纳入标准包括研究SRT/SRS技术治疗各种癌症的所有类型的经济评估研究。
■共包括47篇文章。研究结果表明，使用直线加速器技术治疗肺癌（12项研究中的8项）和前列腺癌（5项研究中的4项）是一种具有成本效益的策略。发现线性加速器在治疗肝转移和肝癌方面具有成本效益（5项研究中有2项）。所有在脑转移中使用伽玛刀技术的纳入研究都报道了伽玛刀是一种具有成本效益的治疗方法。此外，在前列腺癌和肝癌的治疗中，与其他治疗相比,质子治疗被认为是一种具有成本效益的选择.
■这项研究证实，SRT/SRS是用于治疗各种类型癌症的具有成本效益的程序。因此,建议使用SRT/SRS技术以优化资源使用。
